全文获取类型
收费全文 | 3212576篇 |
免费 | 245596篇 |
国内免费 | 8153篇 |
专业分类
耳鼻咽喉 | 43696篇 |
儿科学 | 104453篇 |
妇产科学 | 87198篇 |
基础医学 | 462035篇 |
口腔科学 | 89430篇 |
临床医学 | 292684篇 |
内科学 | 629677篇 |
皮肤病学 | 73385篇 |
神经病学 | 257542篇 |
特种医学 | 124063篇 |
外国民族医学 | 743篇 |
外科学 | 488302篇 |
综合类 | 70594篇 |
现状与发展 | 14篇 |
一般理论 | 1167篇 |
预防医学 | 257170篇 |
眼科学 | 73460篇 |
药学 | 235386篇 |
15篇 | |
中国医学 | 5970篇 |
肿瘤学 | 169341篇 |
出版年
2018年 | 35052篇 |
2017年 | 26740篇 |
2016年 | 30741篇 |
2015年 | 34572篇 |
2014年 | 48666篇 |
2013年 | 73522篇 |
2012年 | 97245篇 |
2011年 | 103934篇 |
2010年 | 62876篇 |
2009年 | 60044篇 |
2008年 | 97271篇 |
2007年 | 103794篇 |
2006年 | 105156篇 |
2005年 | 102003篇 |
2004年 | 97327篇 |
2003年 | 94185篇 |
2002年 | 90875篇 |
2001年 | 146410篇 |
2000年 | 150262篇 |
1999年 | 126689篇 |
1998年 | 38030篇 |
1997年 | 33515篇 |
1996年 | 34243篇 |
1995年 | 33248篇 |
1994年 | 30741篇 |
1993年 | 28932篇 |
1992年 | 100962篇 |
1991年 | 98526篇 |
1990年 | 95841篇 |
1989年 | 92023篇 |
1988年 | 84923篇 |
1987年 | 83379篇 |
1986年 | 78505篇 |
1985年 | 75497篇 |
1984年 | 56886篇 |
1983年 | 48321篇 |
1982年 | 29341篇 |
1981年 | 26424篇 |
1979年 | 52195篇 |
1978年 | 37564篇 |
1977年 | 31354篇 |
1976年 | 29695篇 |
1975年 | 31623篇 |
1974年 | 37747篇 |
1973年 | 35908篇 |
1972年 | 33766篇 |
1971年 | 31649篇 |
1970年 | 29010篇 |
1969年 | 27625篇 |
1968年 | 25454篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
993.
A. Bersano L. Candelise R. Sterzi G. Micieli M. Gattinoni A. Morabito 《Neurological sciences》2006,27(5):332-339
Abstract The future challenge for improving stroke patients’ outcome will be to implement new Stroke Units (SUs) worldwide. However
the best SU model remains uncertain. The aim of this study was to evaluate the number of SUs and the quality characteristics
of acute stroke care in Italy. We conducted a SU survey in Italy, interviewing the directors of the hospital wards that discharged
at least 50 acute stroke patients a year. A SU was defined as an acute ward area with stroke-dedicated beds and staff. To
compare the quality of care provided in SUs with that in general wards (GWs) we investigated the characteristics of five domains:
hospital setting, unit setting, staffing, process of care and diagnostic investigations. We identified 68 SUs and 677 GWs.
Multivariate logistic regression analyses demonstrated that SUs compared to GWs had higher quality scores in unit setting
(ROC area=0.9721), staffing (ROC area=0.8760) and care organisation (ROC area=0.7984). The hospital setting (ROC area=0.7033)
and the availability of rapid diagnostic investigations (ROC area=0.7164) had lower power in discriminating SU from GW. In
Italy in 2003/04 only 9% of the hospital services had organised SU care. The study demonstrated that SUs admitted more than
100 patients per year, had more monitoring equipment and staffing time, and practised multidisciplinary meetings and early
mobilisation. The utility of these structural and performance characteristics needs validation from outcome studies. 相似文献
994.
Asawanonda P. Chingchai A. Torranin P. 《世界核心医学期刊文摘》2006,2(3):25-25
目的:确定UVB靶向光疗治疗局限性银屑病是否安全有效及是否存在量效关系。设计:随机、对评估者设盲对照研究。机构:泰国曼谷大学医院皮肤病门诊。患者:14例稳定性局限性斑块型银屑病患者。干预:依据预定的最小红斑量(M EDs),随机给予患者不同通量的UVB靶向光线治疗,3次/周。在4 相似文献
995.
Willemijn A K M Windt Atsua Tahara Alex C A Kluppel Dick de Zeeuw Robert H Henning Richard P E van Dokkum 《Journal of the renin-angiotensin-aldosterone system》2006,7(4):217-224
INTRODUCTION: Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). MATERIALS AND METHODS: After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7). RESULTS: In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44+7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67+7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30+18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21+20% and 0%, respectively), ACE-I significantly lowered proteinuria (92+2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed. CONCLUSION: These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage. 相似文献
996.
997.
998.
999.
Robin L. Bissinger MSN RNC NNP Cheryl A. Carlson MS RNC NNP 《Newborn and Infant Nursing Reviews》2006,6(2):87
Surfactant, a complex substance containing specific proteins and phospholipids, is essential for gas exchange in the lungs. Research shows that surfactant not only lowers surface tension, but also plays a role in host defense. Surfactant replacement therapy is a cornerstone in the treatment of respiratory distress syndrome in premature infants. New information on endogenous surfactant composition including surfactant apoproteins has led to advances in the surfactant replacement products currently available. Because of the success of surfactant deficiency treatment in neonates, surfactant replacement therapy has been studied in both the pediatric and adult population for the treatment of other respiratory disorders. This article describes the composition, metabolism, and function of endogenous surfactant and other uses of surfactant replacement therapies in neonates. 相似文献
1000.
Targeted silencing of disease-associated genes by synthetic short interfering RNA (siRNA) holds considerable promise as a novel therapeutic strategy. However, unmodified siRNA can be potent triggers of the innate immune response, particularly when associated with delivery vehicles that facilitate intracellular uptake. This represents a significant barrier to the therapeutic development of siRNA due to toxicity and off-target gene effects associated with this inflammatory response. Here we show that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. These noninflammatory siRNA, containing less than 20% modified nucleotides, can be readily generated without disrupting their gene-silencing activity. We show that, coupled with an effective systemic delivery vehicle, 2'OMe-modified siRNA targeting apolipoprotein B (apoB) can mediate potent silencing of its target mRNA, causing significant decreases in serum apoB and cholesterol. This is achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. This approach to siRNA design and delivery should prove widely applicable and represents an important step in advancing synthetic siRNA into a broad range of therapeutic areas. 相似文献